On September 8, 2022 Philogen S.p.A., a clinical-stage biotechnology company focused on antibody and small
molecule-based targeted therapeutics, reported the conferences its management team will be participating in the coming months (Press release, Philogen, SEP 8, 2022, View Source [SID1234619229]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress 2022, 9-13 September
European Association of Neuro-Oncology (EANO) Congress 2022, 15-18 September
Emerging Technologies and Methodologies in Small Molecule Drug Discovery & Synthesis Symposium, 27-29
September
• From Encoded Combinatorial Libraries To Targeted Therapeutics, Prof. Dr. Dario Neri, Co-founder, Chief Executive and Chief Scientific Officer (28 September)
Festival of Biologics Basel 2022, 2-4 November
• Tripokin: tumor-targeted delivery of IL2 potentiated by TNF, Roberto De Luca, PhD, Head of Antibody
Therapeutics (2 November)
• Small Molecule Therapeutics targeting Fibroblast Activation Protein in the tumor microenvironment of solid tumors, Samuele Cazzamalli, Head of Small Molecule Therapeutics (2 November)
10th International Symposium on DNA-Encoded Chemical Libraries, 3-4 November
• Quantification of DEL selections and implications for good selection protocols, Prof. Dr. Dario Neri, Co-founder,
Chief Executive and Chief Scientific Officer (November 3)
The Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper)’s (SITC) (Free SITC Whitepaper) 37th Annual Meeting 2022, 8-12 November
• Combinatorial chemoimmunotherapy based on the antibody-cytokine fusion protein L19TNF unleashes potent
anti-tumor immunity against treatment-refractory glioblastoma, Teresa Hemmerle, PhD, Senior Project Manager
• A novel IL12-based immunocytokine targeting Fibroblast Activation Protein (FAP) for the treatment of cancer,
Roberto De Luca, PhD, Head of Antibody Therapeutics
• Decreasing toxicity of immunocytokines by transient and selective inhibition of their intracellular signaling
activation, Sheila Dakhel, PhD, Senior Scientist
• A novel fully human CD28 antibody that cross-reacts with CTLA-4 and mouse CD28 for potential applications in
cancer immunotherapy, Abdullah Eisayed, PhD student at Philogen
14th Annual PEGS Europe Protein & Antibody Engineering Summit 2022, 14-16 November
• Antibody-cytokine fusions: emerging clinical data in glioblastoma, sarcoma and dermato-oncology indications,
Prof. Dr. Dario Neri, Co-founder, Chief Executive and Chief Scientific Officer
TIDES Europe 2022, 16-18 November
• Non-internalizing Small Molecule-Drug Conjugates and Radioligand Therapeutics targeting Fibroblast Activation
Protein in solid lesions, Samuele Cazzamalli, Head of Small Molecule Therapeutics